Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 157 of 6351
-
Can a new pill rescue patients when standard leukemia drugs stop working?
Disease control Recruiting nowIn a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173 subjects are e…
Phase 3 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New Antibody-Chemo combo shows promise in slowing stomach cancer
Disease control OngoingZolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab …
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a common heart drug cut COPD hospitalizations?
Disease control CompletedBackground: In patients with chronic obstructive pulmonary disease (COPD) and concomitant cardiovascular conditions cardio-selective beta-blockers reduce mortality and can be used without significant negative effects on lung function or respiratory symptoms. Observational studies…
Phase 4 • Sponsor: Ole Frobert, MD, PhD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo therapy shows promise for advanced uterine cancer
Disease control CompletedThis is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab…
Phase 3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail aims to fight advanced liver cancer
Disease control OngoingThis Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantin…
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can freezing ovaries before cancer treatment preserve a Child's future fertility?
Disease control Recruiting nowThe purpose of this study is to safely remove ovarian tissue in pre-pubertal pediatric patients, who are at risk for infertility from their medical treatment, for freezing for future restoration of fertility and hormone function.
Sponsor: Erin Rowell • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could a PET scan spare throat cancer patients from High-Dose radiation?
Disease control CompletedThis prospective study aims to utilize pre- and mid-treatment PET-CT to guide de-escalation of radiation therapy in HPV-related squamous cell carcinoma of the oropharynx.
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Promising new combo therapy aims to improve survival in kids with aggressive nerve cancer
Disease control Recruiting nowThis phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not har…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Immune cell therapy shows promise against rare eye cancer
Disease control OngoingThis is a Phase 2 study in which the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with metastatic uveal melanoma will be evaluated. Metastatic uveal melanoma (UM) carries a poor p…
Phase 2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Own stem cells Gene-Hacked to fight rare hurler syndrome
Disease control OngoingThis is a phase I/II study evaluating safety and efficacy of autologous hematopoietic stem and progenitor cells genetically modified with IDUA lentiviral vector encoding for the human α-L-iduronidase gene for the treatment of patients affected by Mucopolysaccharidosis Type I, Hur…
Phase 1/2 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Electric field device shows promise in tough pancreatic cancer trial
Disease control CompletedBrief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.T…
Phase 3 • Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take aim at High-Risk multiple myeloma
Disease control OngoingThis is an open-label, phase 1 study to assess the safety, pharmacodynamics, and anti-myeloma effects of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains (referred to …
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
Cure OngoingThe main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow cancer. The combination of chemotherapy and radiation d…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
New pill shows promise for rare kidney cancer in VHL patients
Disease control OngoingThis study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.
Phase 2 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Probiotic shows promise in preventing Life-Threatening transplant complication in kids
Prevention OngoingThis randomized phase III trial studies how well Lactobacillus plantarum works in preventing acute graft versus host disease in children undergoing donor stem cell transplant. Lactobacillus plantarum may help prevent the development of gastrointestinal graft versus host disease i…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Prevention
Last updated Jun 27, 2026 07:54 UTC
-
New shot cuts bleeding in hemophilia a patients
Disease control CompletedThis multicenter, open-label, Phase 3 study with randomized and non-randomized arms is designed to investigate the efficacy, safety, and pharmacokinetics of emicizumab in participants with hemophilia A regardless of factor VIII (FVIII) inhibitor status. Participants greater than …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can an immunotherapy combo keep lung cancer from coming back after surgery?
Disease control OngoingThis trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable s…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can kidneys from HIV-Positive donors save more lives?
Disease control CompletedThe primary objective of this study is to determine if an HIV-infected deceased kidney donor (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications.
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can an immune booster keep liver cancer away?
Disease control OngoingThis study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug duo aims to outsmart advanced melanoma
Disease control OngoingThe purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 15:12 UTC